DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com

Research analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVTGet Free Report) in a report released on Tuesday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright dropped their price objective on shares of DBV Technologies from $20.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th.

View Our Latest Analysis on DBV Technologies

DBV Technologies Stock Performance

Shares of DBVT stock opened at $0.80 on Tuesday. DBV Technologies has a fifty-two week low of $0.50 and a fifty-two week high of $3.70. The firm has a market capitalization of $77.10 million, a price-to-earnings ratio of -0.95 and a beta of 0.69. The stock’s 50-day simple moving average is $1.02 and its 200-day simple moving average is $1.43.

DBV Technologies (NASDAQ:DBVTGet Free Report) last released its earnings results on Tuesday, May 7th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.16. DBV Technologies had a negative net margin of 530.89% and a negative return on equity of 56.76%. The company had revenue of $1.41 million during the quarter, compared to analysts’ expectations of $3.20 million. As a group, equities analysts forecast that DBV Technologies will post -1.22 earnings per share for the current year.

Institutional Trading of DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC bought a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVTFree Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 50,986 shares of the company’s stock, valued at approximately $49,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

(Get Free Report)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

Further Reading

Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.